Abstract
Sjogren’s syndrome is a chronic autoimmune connective tissue disorder characterised by lymphocytic infiltration of salivary and lacrimal glands with consequent xerophthalmia and xerostomia. Sicca symptoms have successfully been treated with both topical and systemic agents, although immunosuppressive agents have not been successful in modifying the progression of the disease. Three inventions that may have a potential in modifying this disease process, as well as an invention improving an already available topical measure for xerophthalmia will be reviewed. A better understanding of the pathogenesis of this disorder will lead to an agent with disease modifying effects.